Fundraising FoxAisling Capital — 2019 Investments
5 investments dated 2019 · listed companies and verified rows first · show all
Nuvation Bio is a global oncology company that develops novel cancer therapies through its own drug discovery programs and business development, serving cancer patients.
BiotechHealthtechNew York, US
David Hung(Founder)inDavid Hanley(Chief Technical Operations Officer)inGary Hattersley(Chief Scientific Officer)inStacy Markel(Chief People Officer)inPhilippe Sauvage(Chief Financial Officer)inColleen Sjogren(Chief Commercial Officer)in
Co-investorsDecheng CapitalEcoR1 CapitalVertex Ventures ChinaOmega Funds
Catalent is a global Contract Development and Manufacturing Organization (CDMO) that helps pharma, biotech, and self-care companies develop, manufacture, and deliver drug products and consumer health solutions.
Advanced ManufacturingBiotechHealthtechSomerset, US
John R. Chiminski(Executive Officer, Director)inWetteny Joseph(Executive Officer)inDonald E. Morel Jr.(Director)Peter Zippelius(Director)
BoardJack L. Stahl(Director)Madhavan Balachandran(Director)
Co-investorsHavencrest Capital ManagementLeonard GreenBlackstone
Chimerix is a biopharmaceutical company developing therapies for rare diseases and cancers, with a focus on advancing treatments through biomarker-driven approaches and precision medicine.
BiotechHealthtechMedical DevicesDurham, US
Mike Sherman(Chief Executive Officer and President)W. Garrett Nichols(Chief Medical Officer)Michael A. Alrutz(Executive Officer)Randall Lanier(Chief Science Officer)Roy W. Ware(Chief Manufacturing and Technology Officer)Heather Knight-Trent(Vice President of Regulatory Affairs)
Co-investorsAlta PartnersAsset Management CompanyCanaan PartnersFrazier Life SciencesPappas CapitalSanderling Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.